Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allovir Inc (NQ: ALVR )

3.960 +0.240 (+6.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 146,312
Open 3.810
Bid (Size) 3.700 (1)
Ask (Size) 4.180 (2)
Prev. Close 3.720
Today's Range 3.700 - 3.970
52wk Range 3.170 - 10.29
Shares Outstanding 93,588,013
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
From AlloVir
Via Business Wire
AlloVir: Q1 Earnings Insights
 
Via Benzinga

Performance

YTD
-24.28%
-24.28%
1 Month
+2.59%
+2.59%
3 Month
-35.29%
-35.29%
6 Month
-49.03%
-49.03%
1 Year
+12.18%
+12.18%

More News

Read More
AlloVir Reports First Quarter 2023 Financial Results
From AlloVir
Via Business Wire
AlloVir to Present at the BofA Securities 2023 Health Care Conference
From AlloVir, Inc.
Via Business Wire
AlloVir's Posoleucel Achieves Non-Relapse Mortality Of 0% In Transplant Patients For Viral Infections
Via Benzinga
AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023
From AlloVir, Inc.
Via Business Wire
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
From AlloVir
Via Business Wire
AlloVir Announces Final Results From Posoleucel Study In Kidney Transplant Recipients With BK Viremia, Shares Fall
Via Benzinga
AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook
From AlloVir, Inc.
Via Business Wire
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
From AlloVir, Inc.
Via Business Wire
AlloVir to Participate in the SVB Securities Global Biopharma Conference
From AlloVir, Inc.
Via Business Wire
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
From AlloVir, Inc.
Via Business Wire
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
From AlloVir, Inc.
Via Business Wire
AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition
From AlloVir
Via Business Wire
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
From AlloVir
Via Business Wire
AlloVir: Q3 Earnings Insights
Via Benzinga
Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting
From AlloVir, Inc.
Via Business Wire
AlloVir Reports Third Quarter 2022 Financial Results
From AlloVir, Inc.
Via Business Wire
Moderna, Zscaler And This Biotechnology Stock Insiders Are Selling
Via Benzinga
Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From AlloVir, Inc.
Via Business Wire
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.